Interferon alpha-2b biosimilar (Reliance Life Sciences)

干扰素α-2b生物类似药 (Reliance Life Sciences)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon alpha-2b biosimilar (Reliance Life Sciences)
Drug Alias Name干扰素α-2b生物仿制药 (Reliance Life Sciences)recombinant human interferon alpha 2bRecombinant Interferon αReliFeron
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant cytokinesBiologics > Biosimilar
Mechanisms of ActionImmunostimulantsInnate antiviral immune response inducersInterferon alpha/beta receptor agonists
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMelanomaHepatitis CSarcoma, Kaposi +[5] 
Global Approved IndicationsMelanomaHepatitis CSarcoma, Kaposi +[5] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryIndia
Original Approved Date2008/01/01
Country/TerritoryIndia
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesReliance Life Sciences
China Registration ClassN/A

Develop Information

Active CompaniesReliance Life Sciences
Inactive CompaniesN/A
Active IndicationsMelanomaHepatitis CSarcoma, Kaposi +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeL03AB05
Related LinksN/A